Summary
Viatris Inc., based in Pennsylvania, is a specialty and generic drug company formed in 2020 through the combination of Pfizer’s Upjohn business and Mylan N.V. The shares are a component of the S&P 500. The company has 37,000 employees. Viatris has scientific, manufacturing, distribution, and regulatory expertise, and serves patients in more than 165 countries and territories. The company’s portfolio includes more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both noncommunicable and infectious diseases. Its products include complex generic and branded medicines and over-the-counter consumer products. The company’s near-term plans include integrating its businesses and deleveraging; this is expected to take three years. In the medium term, the company plans to achieve cost synergies
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
EMEA Tribune is not involved in this news article, it is taken from our partners and or from the News Agencies. Copyright and Credit go to the News Agencies, email news@emeatribune.com Follow our WhatsApp verified Channel
